Effects of Common Thrombophilia Factor Mutations in Central Retinal Vein Occlusion

Overview

Journal Beyoglu Eye J

Publisher Kare Publishing

Specialty Ophthalmology

Date 2022 Feb 21

PMID 35187427

Authors

Muhammer Ozgur Cevik

Sadik Gorkem Cevik

Affiliations

Soon will be listed here.

Abstract

Objectives: Central retinal vein occlusion (CRVO) is a severe eye disease that impairs vision. Although numerous systemic conditions have been reported to be a contributor, its exact pathophysiology has not yet been resolved. The purpose of this study was to study the role of some common thrombophilic polymorphisms in CRVO patients.

Methods: A total of 33 CRVO patients (25 non-ischemic CRVO and 8 ischemic CRVO) and 30 controls were recruited. Factor V Leiden (G1691A), prothrombin (Factor II G20210A), MTHFR (C677T), MTHFR (A1298C), and PAI-1 5G/4G polymorphisms in venous blood DNA samples were examined, as well as the presence of hypertension, diabetes mellitus, glaucoma, smoking, and history of thrombosis.

Results: It was determined that MTHFR C677T polymorphisms, either in heterozygous or homozygous form, might be a risk factor for CRVO and systemic thrombosis. No differences were detected between the CRVO and control groups in terms of diabetes mellitus (p=0.058>0.05), hypertension (p=0.3>0.05), smoking (p=0.923>0.05), glaucoma (p=0.06>0.05) or use of anticoagulant drugs (p=0.4>0.05). Analysis of patient history revealed a statistically significant difference regarding a thrombotic event in the medical history of the CRVO group (p=0.001<0.05; n=4) versus the control group. The ischemic CRVO group had a significantly higher incidence of diabetes mellitus (p=0.002<0.05) and hypertension (p=0.031<0.05) than the non-ischemic CRVO group.

Conclusion: The MTHFR C677T mutation appears to be a risk factor for CRVO but factor V Leiden (G1691A), prothrombin (Factor II G20210A), MTHFR (A1298C), and PAI-1 5G/4G mutations were not determined to be specifically related to CRVO in this study. The presence of diabetes mellitus and hypertension was significant in the ischemic CRVO group. Further studies with larger sample sizes should be conducted.

Citing Articles

Highlights on Genetic Polymorphism Associated with Thromboembolic Risk; Implications in Ophthalmic and Autoimmune Disorders-A Review.

Romanitan M, Popa-Cherecheanu M, Vasile V, Stanca S, Iancu G, Zemba M Diagnostics (Basel). 2023; 13(7).

PMID: 37046485 PMC: 10093669. DOI: 10.3390/diagnostics13071267.

References

Andreassi M, Botto N, Maffei S . Factor V Leiden, prothrombin G20210A substitution and hormone therapy: indications for molecular screening. Clin Chem Lab Med. 2006; 44(5):514-21. DOI: 10.1515/CCLM.2006.103. View

Marcucci R, Sofi F, Grifoni E, Sodi A, Prisco D . Retinal vein occlusions: a review for the internist. Intern Emerg Med. 2011; 6(4):307-14. DOI: 10.1007/s11739-010-0478-2. View

Li D, Zhou M, Peng X, Sun H . Homocysteine, methylenetetrahydrofolate reductase C677T polymorphism, and risk of retinal vein occlusion: an updated meta-analysis. BMC Ophthalmol. 2014; 14:147. PMC: 4255450. DOI: 10.1186/1471-2415-14-147. View

Gao W, Wang Y, Zhang P, Wang H . MTHFR C677T mutation in central retinal vein occlusion: a case-control study in Chinese population. Thromb Res. 2007; 121(5):699-703. DOI: 10.1016/j.thromres.2007.05.026. View

Rosendaal F, Reitsma P . Genetics of venous thrombosis. J Thromb Haemost. 2009; 7 Suppl 1:301-4. DOI: 10.1111/j.1538-7836.2009.03394.x. View

Esmaili D, Boyer D . Recent advances in understanding and managing retinal vein occlusions. F1000Res. 2018; 7:467. PMC: 5904724. DOI: 10.12688/f1000research.12886.1. View

Russo P, Damante G, Pasca S, Turello M, Barillari G . Thrombophilic mutations as risk factor for retinal vein occlusion: a case-control study. Clin Appl Thromb Hemost. 2014; 21(4):373-7. DOI: 10.1177/1076029614522544. View

Rogers S, McIntosh R, Cheung N, Lim L, Wang J, Mitchell P . The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and Australia. Ophthalmology. 2009; 117(2):313-9.e1. PMC: 2945292. DOI: 10.1016/j.ophtha.2009.07.017. View

Ferrazzi P, Di Micco P, Quaglia I, Rossi L, Bellatorre A, Gaspari G . Homocysteine, MTHFR C677T gene polymorphism, folic acid and vitamin B 12 in patients with retinal vein occlusion. Thromb J. 2005; 3:13. PMC: 1224880. DOI: 10.1186/1477-9560-3-13. View

10.

Klein R, Moss S, Meuer S, Klein B . The 15-year cumulative incidence of retinal vein occlusion: the Beaver Dam Eye Study. Arch Ophthalmol. 2008; 126(4):513-8. DOI: 10.1001/archopht.126.4.513. View

11.

Kuhli-Hattenbach C, Hellstern P, Nagler D, Kohnen T, Hattenbach L . Prothrombin polymorphism A19911G, factor V HR2 haplotype A4070G, and plasminogen activator-inhibitor-1 polymorphism 4G/5G and the risk of retinal vein occlusion. Ophthalmic Genet. 2017; 38(5):413-417. DOI: 10.1080/13816810.2016.1244694. View

12.

Yioti G, Panagiotou O, Vartholomatos G, Kolaitis N, Pappa C, Evangelou E . Genetic polymorphisms associated with retinal vein occlusion: a Greek case-control study and meta-analysis. Ophthalmic Genet. 2013; 34(3):130-9. DOI: 10.3109/13816810.2012.746376. View

13.

Ulisse S, Baldini E, Sorrenti S, DArmiento M . The urokinase plasminogen activator system: a target for anti-cancer therapy. Curr Cancer Drug Targets. 2009; 9(1):32-71. DOI: 10.2174/156800909787314002. View

14.

Liew S, Das Gupta E . Methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism: epidemiology, metabolism and the associated diseases. Eur J Med Genet. 2014; 58(1):1-10. DOI: 10.1016/j.ejmg.2014.10.004. View

15.

Sivaprasad S, Amoaku W, Hykin P . The Royal College of Ophthalmologists Guidelines on retinal vein occlusions: executive summary. Eye (Lond). 2015; 29(12):1633-8. PMC: 5129788. DOI: 10.1038/eye.2015.164. View

16.

Kolar P . Risk factors for central and branch retinal vein occlusion: a meta-analysis of published clinical data. J Ophthalmol. 2014; 2014:724780. PMC: 4070325. DOI: 10.1155/2014/724780. View

17.

Zou Y, Zhang X, Zhang J, Ji X, Liu Y . G1691A is associated with an increased risk of retinal vein occlusion: a meta-analysis. Oncotarget. 2017; 8(43):75467-75477. PMC: 5650437. DOI: 10.18632/oncotarget.20636. View

18.

Wang J, Wang C, Chen N, Shu C, Guo X, He Y . Association between the plasminogen activator inhibitor-1 4G/5G polymorphism and risk of venous thromboembolism: a meta-analysis. Thromb Res. 2014; 134(6):1241-8. DOI: 10.1016/j.thromres.2014.09.035. View

19.

Burzotta F, Di Castelnuovo A, Amore C, DOrazio A, Di Bitondo R, Donati M . 4G/5G promoter PAI-1 gene polymorphism is associated with plasmatic PAI-1 activity in Italians: a model of gene-environment interaction. Thromb Haemost. 1998; 79(2):354-8. View

20.

Hayreh S . Prevalent misconceptions about acute retinal vascular occlusive disorders. Prog Retin Eye Res. 2005; 24(4):493-519. DOI: 10.1016/j.preteyeres.2004.12.001. View